BioSpace News Archive

Cortexyme, Inc. (Nasdaq: CRTX) today announced that its GAIN Trial for Alzheimer’s disease (AD) has exceeded its enrollment target of 570 patients. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of atuzaginstat (COR388), Cortexyme’s lead investigational medicine, in patients with mild to mode

OPTEC International, Inc announced that it has secured a $5,000,000+ funding approval with California based RB Capital Partners, Inc.

OncoImmune’s SACCOVID ™ (CD24Fc) Exhibits Superb Therapeutic Efficacy—A Potential Breakthrough in Treating Severe and Critical COVID-19

Halberd Corporation clarifies next steps in their unique research with Arizona State University. Halberd directed their research program to focus on that element of Covid-19 which makes the disease most contagious - the spike antigen.

Parexel , a leading provider of solutions to accelerate the development and delivery of innovative new therapies to market to improve world health, from Clinical through Commercialization, in collaboration with Innoplexus, a leader in artificial intelligence (AI) analytics, today launched the COVID-1 9 Clearinghouse , a comprehensive online resource for patients, researchers and clinical trial sponsors to di

Rarecells Diagnostics (France), a leading liquid biopsy company, is pleased to announce that the University Medical Center of Groningen, The Netherlands, has published research comparing the performance of the ISET® technology to the reference antibody-based system in Non-Small Cells Lung Cancer (NSCLC) demonstrating key advantages of the ISET® technology.

Riffyn Inc. and Imperial College today announce a public/private partnership to bring Riffyn’s process data system, Riffyn Nexus, to the public synthetic biology research community in the UK.

CURE Pharmaceutical Holdings (OTC: CURR) today announced its definitive agreement to acquire Sera Labs, Inc. The closing is anticipated to occur in early October. As previously announced, the transaction consists of an up-front payment of $20 million, of which $1 million was paid in cash and $19 million has been allocated in CURE stock at a valuat

FH Ortho Inc, a long standing, well respected manufacturer of innovative orthopedic devices proudly announces the U.S. launch of the Arrow Prime Advanced Instrumentation for shoulder arthroplasty.

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced it will host a key opinion leader (KOL) call on oral tebipenem HBr for the treatment of complicated urinary tract infections on Wednesday, September 30, 2020